Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 7,051 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Overweight, Obesity
Interventions: NNC0662-0419, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Chronic Graft-versus-host Disease
Interventions: Itacitinib, Placebo, Methylprednisolone, Prednisone; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 39
States / cities: Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 30 more

Conditions: Healthy Volunteers, Drug Users
Interventions: EB-1020 400 mg, EB-1020 800 mg, lisdexamfetamine 150 mg, d-amphetamine 40 mg, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Multiple Sclerosis
Interventions: IMU-838, Placebo matching IMU-838; Drug
Lead sponsor: Immunic AG; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 8
States / cities: Coral Springs, Florida • Naples, Florida • Ormond Beach, Florida + 5 more

Conditions: Fatty Liver Disease
Interventions: JNJ-75220795, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Hollywood, Florida • San Antonio, Texas

Conditions: Dental Pain
Interventions: Acetaminophen ER, Placebo; Drug
Lead sponsor: McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.; Industry
Eligibility: 17 Years to 45 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Post Traumatic Stress Disorder
Interventions: Intervention D SLS-002, Intervention D Placebo; Drug
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2028 – 2029
U.S. locations: 9
States / cities: Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more

Conditions: Kidney Failure, Chronic
Interventions: LY3113593, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Glendale, California • Orlando, Florida • Minneapolis, Minnesota

Conditions: Long COVID, PASC Post Acute Sequelae of COVID 19
Interventions: Valacyclovir celecoxib dose 1, Valacyclovir celecoxib dose 2, Placebo; Drug
Lead sponsor: Bateman Horne Center; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Coronary Disease
Interventions: RUC-4 Compound; Drug
Lead sponsor: CeleCor Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypertension
Interventions: Azilsartan Medoxomil, Olmesartan, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 449 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 46
States / cities: Huntsville, Alabama • Ozark, Alabama • Mesa, Arizona + 43 more

Conditions: Osteoarthritis, Hip
Interventions: Synvisc-One (hylan G-F 20), Placebo; Device
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 35 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 45
States / cities: Burmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 41 more

Conditions: Healthy Subjects
Interventions: AC-076 for s.c. administration, Placebo; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Parkinson's Disease
Interventions: LY3154207, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Glendale, California • Orlanda, Florida • The Villages, Florida

Conditions: Healthy Adult Subjects, Sickle Cell Disease
Interventions: FTX-6058/placebo oral capsule(s), FTX-6058 - Two Dosing Periods, FTX-6058 / Midazolam Syrup; Drug
Lead sponsor: Fulcrum Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Atlanta, Georgia • Overland Park, Kansas

Conditions: Chronic Renal Insufficiency
Interventions: LHW090, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Orlando, Florida • Knoxville, Tennessee

Conditions: Adult Subject
Interventions: Ingestion of Water; Other
Lead sponsor: Inhale, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Westlake Village, California

Conditions: Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Interventions: Nerandomilast, Placebo matching nerandomilast; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 414 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 31
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 25 more

Conditions: Prader-Willi Syndrome
Interventions: CBDV Compound, Placebo; Drug
Lead sponsor: Eric Hollander; Other
Eligibility: 5 Years to 30 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Hearing Loss, Cancer
Interventions: SPI-1005, Placebo; Drug
Lead sponsor: Sound Pharmaceuticals, Incorporated; Industry
Eligibility: 19 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Generalized Anxiety Disorder
Interventions: sertraline 50 mg daily, sertraline 100 mg daily, Placebo 50 or 100 mg; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 3
States / cities: Tuscaloosa, Alabama • Miami, Florida • Charleston, South Carolina

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 11
States / cities: Los Angeles, California • Santa Barbara, California • Torrance, California + 7 more

Conditions: Schizophrenia
Interventions: Basmisanil, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 37
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 32 more

Conditions: Type 2 Diabetes Mellitus
Interventions: RO7795081, Semaglutide, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 21
States / cities: Tucson, Arizona • Lake Forest, California • Rancho Cucamonga, California + 18 more

Search by objective public record fields.

A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795

Study of Long-Acting Acetaminophen in Postoperative Dental Pain

Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002

A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis

Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2

A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4

Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension

A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip

A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body

A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease

Safety, Tolerability and Pharmacokinetics of FTX-6058

An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction

Effect of Super-Oxygenated Water on Blood Oxygen Saturation

A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases

CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)

Study to Evaluate the Safety and Pharmacokinetics of SPI-1005

Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics

A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes